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SUMMARY
Objectives: The burden of epilepsy, in terms of both morbidity and mortality, is likely to
vary depending on the etiology (primary [genetic/unknown] vs. secondary [structural/
metabolic]) and with the use of antiepileptic drugs (AEDs). We estimated the disability-
adjusted life years (DALYs) and modeled the remission rates of active convulsive epi-
lepsy (ACE) using epidemiologic data collected over the last decade in rural Kilifi, Kenya.
Methods: We used measures of prevalence, incidence, and mortality to model the
remission of epilepsy using disease-modeling software (DisMod II). DALYs were calcu-
lated as the sum of Years Lost to Disability (YLD) and Years of Life Lost (YLL) due to
premature death using the prevalence approach, with disability weights (DWs) from
the 2010 Global Burden of Disease (GBD) study. DALYs were calculated with R statisti-
cal software with the associated uncertainty intervals (UIs) computed by bootstrapping.
Results: A total of 1,005 (95% UI 797–1,213) DALYs were lost to ACE, which is 433
(95% UI 393–469) DALYs lost per 100,000 people. Twenty-six percent (113/100,000/
year, 95% UI 106–117) of the DALYs were due to YLD and 74% (320/100,000/year, 95%
UI 248–416) to YLL. Primary epilepsy accounted for fewer DALYs than secondary epi-
lepsy (98 vs. 334 DALYs per 100,000 people). Those taking AEDs contributed fewer
DALYs than those not taking AEDs (167 vs. 266 DALYs per 100,000 people). The pro-
portion of people with ACE in remission per year was estimated at 11.0% in males and
12.0% in females, with highest rates in the 0–5 year age group.
Significance: The DALYs for ACE are high in rural Kenya, but less than the estimates
of 2010 GBD study. Three-fourths of DALYs resulted from secondary epilepsy. Use of
AEDs was associated with 40% reduction of DALYs. Improving adherence to AEDs
may reduce the burden of epilepsy in this area.
KEY WORDS: Burden, Disability-adjusted life years, Epilepsy, Remission, Treatment
gap.
Epilepsy is common in low and middle income countries
(LMICs),1 and is associated with considerable mortality and
morbidity2,3 and poor quality of life.4,5 The treatment gap
(the proportion of people with epilepsy [PWE] who do not
receive appropriate treatment) is large (31–100%), espe-
cially in LMICs.6–8
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The World Bank introduced the disability-adjusted life
year (DALY) metric, which incorporates both the morbidity
and mortality of a disease.9,10 DALYs are the sum of Years
Lived with Disability (YLD) and Years of Life Lost (YLL)
due to premature death. The 2010 Global Burden of Disease
(GBD) study estimated that primary epilepsy (cause of epi-
lepsy either genetic or unknown) accounted for 253 DALYs
per 100,000 people globally,11 which amounts to 0.75% of
the total GBD. The disability weights (DWs) used to calcu-
late the YLD component of the DALYs seek to quantify the
health loss from nonfatal diseases and injuries. The DWs
used in the 2010 GBD study ranked severe epilepsy12 higher
than HIV.13
A study from rural China reported that epilepsy caused
208 DALYs per year per 100,000 people (67 YLD, 141
YLL).14 The Kenyan estimate from the GBD 2010 is 550
(95% uncertainty interval [UI] [380–750]) DALYs per
100,000 people; http://viz.healthmetricsandevaluation.org/
gbd-compare/. Because the GBD estimates may not be
directly extrapolated to specific regions within a country
due to different socioeconomic settings, and only estimated
the burden for primary epilepsy, studies are needed to assess
the accuracy of GBD estimates locally and to inform
resource allocation for the prevention and treatment of both
primary and secondary epilepsy.
We established a cohort of people with active convulsive
epilepsy (ACE) from two cross-sectional studies conducted
over a 5-year interval (2003 and 2008) in Kilifi, Kenya. We
studied ACE, since this type of epilepsy is most reliably
detected in community-based studies and is associated with
the greatest mortality and disability. The unadjusted inci-
dence was 37.6 (95% UI 32.7–43.3) per 100,000 persons
per year,15 and the crude prevalence of ACE was 3.0 (95%
UI 2.8–3.2) per 1,000 people.16 The mortality rate was 33.3
(95% UI 25.9–42.8) per 1,000 persons per year with a stan-
dardized mortality ratio of 6.5.17 We have not previously
estimated the percentage of people with ACE who remit or
the DALYs due to epilepsy.
We used data from Kilifi, Kenya, to estimate the remis-
sion and the burden of ACE in terms of YLD, YLL, and the
DALYs. We also computed the DALYs for primary
(genetic/unknown) and secondary (structural/metabolic)
epilepsy, and for those taking and not taking antiepileptic
drugs (AEDs).
Methods
Definition of terms
ACE was defined as having at least two unprovoked
convulsive seizures, with at least one seizure within the last
12 months, which is the criterion for starting antiepileptic
treatment in Kenya.18 We classified ACE as either primary
(genetic/unknown) or secondary (structural/metabolic) epi-
lepsy based on the proximate cause.19 Those with undeter-
mined epilepsy were not included in the analysis. We
classified as secondary epilepsy those who had identifiable
structural/metabolic causes as suggested by history, for
example, head injury or documented infection of the cen-
tral nervous system, and/or detection of focal abnormalities
on clinical and/or electroencephalographic examination, in
accordance with the International League Against Epilepsy
(ILAE) epidemiology guidelines.20 This information was
complete for 747 (99.1%) of the people with ACE. We
have conducted magnetic resonance imaging (MRI) on 152
of these patients who have focal epilepsy, defined as ictal
discharges on electroencephalography and focal clinical
features that are suggestive of identifiable underlying
causes. We did not have adequate data for classifying
seven cases, and these were classified as having undeter-
mined etiology.20 We classified the remainder as having
primary epilepsy. Primary epilepsy was defined as the
absence of identifiable structural/metabolic causes. Epi-
lepsy was classified as being of unknown etiology if ade-
quate evaluation of the available data were not suggestive
of a genetic and secondary cause.
Study setting
This study uses data from Kilifi, a rural area on the Ken-
yan Coast. The framework of the study was within the Kilifi
Health and Demographic Surveillance System (KHDSS),
which covers an area of 189 km2, with about 260,000 resi-
dents. The KHDSS has been used to define the prevalence,
incidence, and mortality of epilepsy, as well as other
common diseases. A community census is carried out every
4–6 months to obtain vital statistics,21 including migrations,
births, and deaths.
Data sources (input parameters)
Population structure and mortality
During a population survey in 2008, we identified 754
people with ACE from the 232,164 people in the KHDSS
and followed them up for 3 years. Data on sociodemograph-
ic and clinical characteristics as well as deaths and causes
of death were collected. This information was used to
construct age and sex population distribution and the num-
ber of deaths in people with and without epilepsy (Table 1).
We used prevalence, incidence, and case fatality to estimate
the remission and duration of ACE using the software pro-
gram DISMOD II (World Health Organization, Geneva,
Switzerland), in which remission is defined as seizure free
for >1 year.22
Prevalence
We used a 2008 cross-sectional survey to determine the
prevalence of ACE. The study employed a three-stage
screening process to identify people with ACE.23 Preva-
lence was calculated as the ratio of clinically confirmed
cases to the population screened. Similarly, prevalence of
primary and secondary epilepsy was calculated as the ratio
Epilepsia, 55(10):1626–1633, 2014
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of the presumed cases with primary and secondary epilepsy
to the total population screened.
Incidence
An original three-stage cross-sectional survey from 2003
identified people with and without ACE, who were followed
for 5 years. The incidence rate used in this study is based on
incident cases identified during the 2008 cross-sectional
study.16,24 Incidence was calculated as the number of inci-
dent cases divided by the person years of observation (PYO)
among the individuals identified during both studies. There
were no data for the 0–5 year band in the 2003 survey, as it
focused on older children and adults. Consequently the inci-
dence rate for this age band could not be calculated. Because
the two studies were 5 years apart, we assumed that those
aged 5 years and younger with prevalent epilepsy in the
2008 survey were all incident cases over the 5-year period,
and to calculate the incidence rate the number of cases was
divided by PYO (in this case PYO was calculated as 2.5
multiplied by the number of children younger than 5 years
of age in the 2008 screened population, which is based on
the assumption that the date of births were normally distrib-
uted over the 5 years). Details on cohort identification are
published elsewhere.15
Case fatality
This is based on a cohort of 232,164 people; 754 diag-
nosed as having ACE were followed from December 2007
with a median (interquartile range) follow-up period of 32.6
(27.7–41.1) months, whereas the general population was
followed for 32.6 (28.5–32.6) months. During this period
there were 3,343 deaths in the total cohort; 61 of these were
people with ACE. The putative causes of death were deter-
mined using World Health Organization (WHO) verbal
autopsy tool, which was administered through a trained
fieldworker to a carer/guardian of the diseased.17 Three
trained clinicians independently assigned the cause of death,
and whenever there were disagreements, another coder
(Charles Newton, neurologist) was involved as an indepen-
dent reviewer. The fourth reviewer examined the records,
and any discrepancies were resolved through consensus; if
consensus was not reached, the cause of death was unclassi-
fied. Cause of death was defined as epilepsy-related if death
occurred during a prolonged seizure or seizure-related acci-
dent or was sudden without a preceding illness.17 While
computing the case fatality for input into DisMod II, deaths
that could not be directly attributed to epilepsy (excess
deaths) were not considered. Case fatality was computed as
the number of deaths (directly attributable to epilepsy)
divided by the number of people with ACE. Similarly, only
the deaths that were attributable to epilepsy were used while
computing the YLL, but these were divided by the period of
follow-up in years.
Analysis
Remission of epilepsy using DisMod II
Data on sex- and age-specific population distribution,
population mortality, incidence, prevalence, and case fatal-
ity were entered into the public domain disease-modeling
software (DisMod II) from WHO (http://www.who.int/
healthinfo/global_burden_disease/tools_software/en/).
DisMod II checks the internal consistency of the input
parameters and uses a set of differential equations to model
the complete epidemiology of a disease using the inter-rela-
tionships between the input variables as shown in Fig-
ure 1.22 Data were smoothed using inbuilt DisMod
mathematical functions, specifically piecewise linear inter-
polation and moving average. In constructing the uncer-
tainty intervals, 1,000 iterations of the DisMod model were
run each time, selecting values from the uncertainty distri-
butions around the input parameters. Results are presented
in six age bands (0–5, 6–12, 13–18, 19–28, 29–49, and 50+
years) for consistency with prior studies published in the
Table 1. Population, total deaths in the population, total deaths in people with epilepsy, and deaths directly
attributable to epilepsy in Kilifi 2008–2010
Age-group (years)
Population
composition
Deaths in the
population People with ACE
Deaths in people
with ACE
Deaths in people
with ACE directly
attributable to
epilepsy
Female Male Female Male Female Male Female Male Female Male
0–5 20,759 21,107 130 171 42 55 3 1 0 0
6–12 26,053 26,194 64 75 76 88 4 5 1 5
13–18 16,691 17,535 42 57 75 83 4 6 2 4
19–28 20,658 16,861 107 74 87 73 9 5 7 3
29–49 25,610 16,660 370 274 53 56 4 6 1 4
50+ 14,137 9,899 959 1,020 35 31 8 6 3 4
Total 123,908 108,256 1,672 1,671 368 386 32 29 14 20
The table shows the distribution of 232,164 people in 2008; 754 had active convulsive epilepsy. By 2010, 3,343 people died, 3,282 without epilepsy and 61 with
epilepsy. There were 34 deaths that were found to be directly attributable to epilepsy.
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same region.15,16 The proportion of PWE who remitted per
year was calculated as 1  e(remission rate), since DisMod II
outputs remission rates.
Disability-adjusted life years
YLL, YLD, and DALYs and their bootstrapped uncer-
tainty intervals (percentile; with 1,000 iterations) were cal-
culated in R, an open-source software for statistical
computing and graphics.25 Bootstrapping was implemented
using the R boot package.26,27 DALYs were computed using
the prevalence approach consistent with the GBD 2010
studies. YLLs for each age group were computed as the
product of the deaths directly attributable to epilepsy and
the standard life expectancy for that age category. The
standard life expectancies were computed from the new
standard reference life table that has a life expectancy at
birth of 86 years for both males and females and was used
in GBD 2010 studies.28 YLD for each age group were calcu-
lated as the product of the prevalence and the disability
weight (DW). Calculation of YLL, YLD, and DALYs for pri-
mary and secondary epilepsy was based on their respective
prevalence ratio and deaths that were directly related to them,
with further analysis examining the effect of taking AEDs.
The calculation of YLD employs the use of DWs. From
the recent GBD studies, there were four DWs associated
with epilepsy: 0.072 for treated seizure-free epilepsy, 0.319
for treated epilepsy with recent seizures, 0.420 for untreated
epilepsy, and 0.657 for severe forms of epilepsy.12 We used
the 2010 GBD study’s mean DW for epilepsy (0.346) for
the sub-Saharan African region (T. Vos, personal communi-
cation). Because the three-stage methodology used to screen
for people with ACE had relatively low sensitivity (46.8%),
we also provide DALY estimates based on adjusted preva-
lence. Unless explicitly stated, the term DALYs refers to
those computed with unadjusted prevalence.
Results
The modeled prevalence of ACE was 3.2 per 1,000 peo-
ple (95% UI 1.1–5.1) for males and 2.6 (95% UI 0.9–4.4)
for females. Incidence estimates were 48.0 (95% UI 10.9–
51.8) and 39.2 (95% UI 7.5–41.9) per 100,000 people per
year in males and females, respectively. The standardized
mortality ratios (SMRs) were significantly higher in males
(10.8, 95% UI 9.3–11.9) than females (8.1, 95% UI 8.1–
8.5), with the highest values in those aged 6–12 years for
males and 50+ for females (Table 2). The proportion of peo-
ple in whom epilepsy remitted per year was estimated at
11.0% (95% UI 0.5–22.2%) in males and 12.0% (95% UI
0.8–22.5%) in females. A higher proportion of people with
ACE who remitted were younger, particularly in those aged
0–5 years at 29.8% per year in males and 30.2% per year in
females (Table 2).
The burden of ACE is provided in both DALYs and
DALY rates (Tables 3 and S1). The total number of DALYs
associated with ACE were estimated at 1,005 (95% UI 797–
1,213), which is 433 (95% UI 393–469) DALYs per
100,000 people. One hundred and thirteen (95% UI 106–
117) DALYs per 1,000 people, or 26% of overall DALYs,
were attributed to YLD, whereas 320 (74%; 95% UI 248–
416), were attributed to YLL. As shown in Table 4, the bur-
den of epilepsy was significantly higher in males (535 DA-
LYs per 100,000 people) than females (344 DALYs per
100,000 people). The highest burden in terms of DALYs
was observed in people aged between 19 and 28 years at
799 per 100,000 people (95%UI 388–997) (Table 3).
One fifth of people with ACE (165/754, 21.9%) had pri-
mary epilepsy, 582 (77.2%) had secondary epilepsy, and 7
(0.9%) had causes that were not diagnosable. The preva-
lence of primary epilepsy was 0.7 per 1,000 (95% UI 0.6–
0.8), whereas that of secondary epilepsy was 2.5 per 1,000
people (95% UI 2.3–2.7). Primary epilepsy contributed
lower DALYs (98 [95% UI 57–137] DALYs per 100,000
people) than secondary epilepsy (334 [95% UI 303–376]
DALYs per 100,000 people) (Table 4). Forty-four percent
(329/754) of those with ACE reported taking AEDs and
were found to contribute significantly lower DALYs (167
[95% UI 136–198] DALYs per 100,000 people) than those
who were not taking AEDs (266 [95% UI 288–333] DALYs
per 100,000 people) (Table 5).
After adjusting the prevalence estimates for the sensitiv-
ity of the three-stage methodology, the total number of
DALYs associated with ACE were estimated at 1,301 (95%
UI 1,154–1,435), which is 561 (95% UI 522–740) DALYs
per 100,000 people. Primary epilepsy contributed 126 (95%
UI 82–143) DALYs and secondary epilepsy 433 (95% UI
386–490) DALYs per 100,000 people. People not taking
AEDs contributed 338 (95% UI 311–420) DALYs, whereas
those taking AEDs contributed 223 (95% UI 205–272)
DALYs per 100,000 people.
Discussion
This study provides modeled estimates of the remission
rate and the burden of primary and secondary epilepsy and
Figure 1.
This diagram represents the complete epidemiology of active con-
vulsive epilepsy (ACE). It shows the interrelationship among the
different states through the hazards (incidence, remission, and
mortality).
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examines the potential influence of AED treatment on the
burden in rural Kenya.We calculated DALYs using a preva-
lence-based approach by inputting available epidemiologic
data collected over a decade in this area. The highest burden
occurred in some of the most economically productive ages
(13–28 years). Remission was estimated at 11% per year in
males and 12% in females, with the highest rates in the
0–5 years old at 30% per year. The computed DALYs for
ACE were 433/100,000 people, whereas those for second-
ary epilepsy were three times more than for primary epi-
lepsy. PWE not taking AEDs contributed 62% of DALYs,
compared to 38% from those taking AEDs.
The adjusted DALYs associated with ACE in this study
are high. This could be ascribed to the use of data from a
resource-poor country, which has high prevalence, inci-
dence, treatment gap, and mortality due to epilepsy. In a
recent meta-analysis, we showed that the median lifetime
prevalence of ACE in rural areas is three times that reported
in urban areas of developing countries.29 This high preva-
lence could be due to high endemicity of associated parasitic
risk factors and perinatal problems.1 With the exception of
the 19–28 age group, our DALYs estimates were slightly
higher in males than females, a result of the significantly
higher mortality observed in males than females (SMR of
10.8 in males [95% UI 9.3–11.9] compared to 8.1 [95% UI
8.1–8.5] in females).
Secondary epilepsy contributes more to the overall bur-
den of epilepsy than primary epilepsy, which, again, is a
reflection of higher mortality in those with secondary
epilepsy (27 deaths) than in those with primary epilepsy
(7 deaths) and also greater severity of illness (higher DWs).
It is likely that acquired epilepsy has a much higher mortal-
ity due to the severity of the underlying causes, such as
tumors, stroke, and encephalopathies. The comparison of
DALYs from primary epilepsy (adjusted and unadjusted) in
this study, differ from the GBD estimate for Kenya of 550
(95% UI 380–750) DALYs per 100,000 people (http://viz.
healthmetricsandevaluation.org/gbd-compare/). This differ-
ence could suggest that the country GBD estimates cannot
be generalized to specific rural parts of a country. In addi-
Table 2. Prevalence, incidence, mean duration of disease, remission, and standardizedmortality ratio estimated in
DisMod II for epilepsy in Kilifi, 2008
Age (years)
Prevalence
per 1,000
Incidence per
100,000/year
Standardized
mortality ratio
Instantaneous
remission rate (%)
Proportion remitting
per year
Male
0–5 2.31 (0.82–3.81) 85.19 (29.05–93.32) 3.23 (3.08–3.25) 35.39 (3.02–68.82) 29.81 (2.97–49.75)
6–12 2.90 (1.03–4.84) 53.07 (7.42–56.75) 16.95 (16.40–17.94) 11.19 (0.00–30.50) 10.59 (0.00–26.29)
13–18 3.84 (1.24–6.62) 39.64 (6.26–42.72) 15.07 (13.39–16.05) 5.80 (0.00–30.50) 5.64 (0.00–26.29)
19–28 3.97 (1.11–5.92) 28.53 (5.93–30.39) 8.87 (8.84–9.34) 6.59 (0.00–13.54) 6.38 (0.00–12.66)
29–49 3.12 (0.99–4.97) 24.07 (6.30–25.64) 5.87 (5.43–6.17) 5.68 (0.00–11.59) 5.52 (0.00–10.94)
50+ 3.13 (1.25–5.16) 43.52 (6.05–46.73) 8.72 (8.21–9.27) 8.59 (0.00–17.62) 8.23 (0.00–16.15)
All ages 3.16 (1.05–5.14) 48.00 (10.92–51.80) 10.80 (9.30–11.90) 11.60 (0.46–25.13) 10.95 (0.46–22.22)
Female
0–5 1.86 (0.63–3.10) 69.44 (14.50–74.37) 1.70 (1.60–1.70) 35.93 (5.59–66.84) 30.18 (5.44–48.75)
6–12 2.42 (0.97–3.92) 48.20 (7.60–50.88) 6.88 (6.67–7.23) 12.74 (0.66–28.61) 11.96 (0.66–24.88)
13–18 3.71 (1.29–6.14) 41.36 (6.77–44.35) 9.79 (9.37–10.26) 5.36 (0.00–10.96) 5.22 (0.00–10.38)
19–28 3.58 (1.20–6.00) 33.83 (5.56–36.69) 7.75 (6.48–7.93) 11.71 (0.00–23.84) 11.05 (0.00–21.21)
29–49 2.06 (0.66–4.10) 14.95 (4.74–15.96) 2.97 (2.79–3.04) 8.13 (0.00–15.94) 7.81 (0.00–14.73)
50+ 2.12 (0.89–3.42) 27.30 (5.46–29.31) 9.91 (9.53–10.47) 9.59 (0.01–19.51) 9.14 (0.01–17.72)
All ages 2.59 (0.92–4.41) 39.16 (7.47–41.89) 8.13 (8.06–8.53) 12.82 (0.79–25.47) 12.03 (0.79–22.49)
To obtain the proportion remitting per year the following formula was used 1 e(remission rate).
Table 3. Active convulsive epilepsy YLL, YLD, and
DALYs per 100,000 population (95% uncertainty
intervals) by age and sex in Kilifi 2008
Age YLL YLD DALYs
Male
0–5 0 (0–0) 89 (85–128) 89 (75–93)
6–12 553 (337–1,015) 118 (107–141) 670 (549–1,341)
13–18 592 (295–893) 164 (148–174) 756 (340–1,041)
19–28 434 (135–434) 150 (135–185) 584 (276–636)
29–49 480 (119–918) 116 (100–127) 596 (356–695)
50+ 440 (331–668) 108 (98–133) 548 (309–567)
All ages 411 (390–443) 123 (113–129) 535 (397–684)
Female
0–5 0 (0–0) 68 (51.7–90) 68 (55–73)
6–12 108 (108–215) 100 (96–112) 207 (89–308)
13–18 314 (0–626) 156 (122–189) 472 (133–503)
19–28 828 (477–1,183) 147 (136–152) 975 (734–1,823)
29–49 76 (0–152) 72 (68–78) 147 (81–156)
50+ 196 (0–310) 86 (69–91) 282 (171–448)
All ages 241 (141–333) 103 (97–112) 344 (287–387)
Male and female
0–5 0 (0–0) 79 (74–89) 79 (80–92)
6–12 331 (220–554) 109 (104–120) 439 (324–718)
13–18 456 (226–458) 161 (141–167) 617 (387–1,004)
19–28 651 (199–894) 149 (129–158) 799 (388–997)
29–49 235 (187–389) 89 (79–91) 324 (129–388)
50+ 297 (249–342) 95 (78–104) 392 (309–687)
All ages 320 (248–416) 113 (106–117) 433 (393–469)
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tion, it could be ascribed to the fact that the GBD study
estimated the burden of both convulsive and nonconvulsive
epilepsy (with nonconvulsive epilepsies forming 44% of all
epilepsies), although it did not include some secondary
causes, for example, stroke, infections of the central nervous
system, or perinatal problems.11,20
The YLL, YLD, and DALYs computed by Ding et al.14
from rural China could not be compared with our estimates,
because they calculated DALYs using the incidence
approach. The prevalence approach has been favored over
the incidence approach by the GBD 2010 team because of
greater data availability and ability to adjust for comorbidi-
ty. The two methods of DALY computation yield different
results.30 It is, however, likely that the burden is higher in
rural Kenya than in China because of the larger treatment
gap in Kilifi,6 compared to the mixed locations (urban and
rural areas) studied in China.8
Among PWE not taking AEDs, mortality was a major
contributor to the DALYs lost, with 22 deaths compared to
12 deaths in those who were on AEDs. A comparison of the
DALYs for those taking and not taking AEDs suggests that
the burden of epilepsy may be substantially reduced by
reducing the high treatment gap in LMICs.6,7 This confirms
the findings by Chisholm et al.31 that up to 40% of the
burden of epilepsy could be reduced by increasing the AED
treatment coverage. In particular, phenobarbital and phenyt-
oin—AEDs widely available in LMICs—are the most
cost-effective based on efficacy and cost of acquisition.31 It
is likely that even more DALYs occur in people who are not
taking AEDs in our study, as information on AED usage
was based on self-reporting, which has been shown to be
unreliable because it often overestimates adherence to
AEDs.6
The modeled remission for both sexes are low com-
pared to those proposed in a review on the natural history
of epilepsy.32 In this cohort, 425/754 (56.4%) (0–5 years
8.8%; 6–12 years 13.4%; 13–18 years 10.2%;
19–28 years 10.9; 29–49 years 7.7%, and 50+ years
5.4%) were not taking AEDs, suggesting that, in most
individuals, remission had occurred spontaneously. In an
earlier study, we found that failure to seek medical treat-
ment and nonadherence to AEDs was associated with the
cost of AEDs, patients’ traditional religious beliefs, nega-
tive attitudes about medical treatment, living far from
health facilities, and negative attitudes about epilepsy.6
The high remission rate in the 0–5 year age group, com-
pared to the other age bands, is similar to what was
observed in Ecuador,33 and supports the finding that early
onset epilepsy tends to remit early in the course of the
condition. The low remission rate may also be associated
with higher proportions of severe epilepsy in Kilifi, which
is suggested by the substantial proportion of PWE with
learning difficulties (27.5%), neurologic deficits (17.6%),
focal neurologic deficits (16.7%), and long duration of
epilepsy (40.9%), all of which have been shown to be
associated with intractable epilepsy.34,35
The major strength of this study is in the use of data from
previous epilepsy studies carried out in the same area and
Table 4. Primary and secondary epilepsy YLL, YLD, andDALYs per 100,000 population (95% uncertainty intervals) by
age and sex in Kilifi 2008
Age (years)
Primary epilepsy Secondary epilepsy
YLL YLD DALYs YLL YLD DALYs
0–5 0 (0–0) 28 (24–35) 28 (22–37) 0 (0–0) 49 (41–65) 49 (47–54)
6–12 54 (0–54) 22 (20–28) 76 (19–130) 277 (220–497) 85 (89–95) 363 (188–523)
13–18 75 (0–150) 25 (20–30) 100 (16–327) 381 (154–611) 133 (120–155) 515 (360–667)
19–28 258 (316–464) 29 (20–32) 287 (88–614) 393 (327–591) 119 (95–145) 512 (374–580)
29–49 46 (0–92) 21 (20–25) 66 (16–161) 189 (47–257) 69 (57–85) 258 (214–353)
50+ 0 (0–0) 25 (9–27) 25 (23–33) 297 (120–449) 71 (62–86) 367 (185–800)
All ages 73 (40–131) 25 (23–26) 98 (57–137) 247 (222–315) 87 (85–90) 334 (303–376)
Table 5. Active convulsive epilepsy YLL, YLD, andDALYs per 100,000 population (95% uncertainty intervals) by age
and sex, andwhether on antiepileptic drugs in Kilifi 2008
Age
Not taking antiepileptic drugs epilepsy Taking antiepileptic drugs epilepsy
YLL YLD DALYs YLL YLD DALYs
0–5 0 (0–0) 54.5 (48–61) 55 (50–63) 0 (0–0) 24 (22–26) 24 (20–30)
6–12 223 (54–390) 66.9 (58–76) 290 (123–354) 107 (0–107) 42 (36–50) 149 (95–149)
13–18 303 (229–305) 78 (70–91) 381 (223–605) 153 (0–307) 83 (83–104) 236 (63–397)
19–28 326 (201–459) 76 (65–86) 401 (198–532) 325 (130–519) 73 (66–86) 398 (131–462)
29–49 184 (47–231) 48 (40–52) 231 (87–598) 51 (0–103) 42 (37–46) 93 (39–102)
50+ 205 (114–197) 59 (39–81) 264 (175–311) 91 (46–139) 36 (30–46) 127 (120–181)
All ages 202 (138–331) 63 (59–67) 266 (288–333) 118 (83–173) 49 (50–53) 167 (136–198)
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with consistent definitions of epilepsy, which is likely to
yield reliable and representative estimates of the burden of
epilepsy in rural Kenya.3 There are some limitations. First,
we only examined ACE, which is likely to underestimate
the burden of epilepsy, as it accounts for only about a third
to half of all epilepsies.36 Second, we had to estimate the
incidence in the under-fives using the 2008 cross-sectional
study, which may differ from actual values. Finally, the sen-
sitivity of the verbal autopsy tool was not measured, but a
physician-certified verbal autopsy has been shown to have a
high sensitivity and specificity for sickle cell disease as well
as the five major causes of death in Kilifi.37,38
Conclusion
The DALYs for ACE are high, particularly in the 6 to 28-
year-old age group. The GBD 2010 overestimates the bur-
den of primary epilepsy in rural Kenya. Secondary epilepsy
was associated with three times more DALYs than primary
epilepsy, and being on AEDs reduced the DALYs by about
40%. Improving adherence to AEDs, thereby reducing the
treatment gap, would likely reduce the burden of epilepsy in
this area.
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